Should Young Men with Intermediate PSA Levels Wait Longer Between Prostate Cancer Screenings? New PROBASE Trial Findings

Table of Contents

• Key Points
• Why This Research Matters
• Understanding the PROBASE Screening Trial
• How the Study Was Conducted
• Key Findings: What the Biopsies Revealed
• Understanding Grade Groups and Prostate Cancer Risk
• What About Grade Group 2 Cancers?
• Active Surveillance: Evidence from PROBASE
• The Case for 5-Year Screening Intervals
• Why MRI Isn't a Simple Solution
• Limitations of the Study
• What This Means for Patients
• Frequently Asked Questions
• Source Information

Key Points

• In the PROBASE trial, 45-year-old men with intermediate PSA levels (1.5–2.99 ng/ml) can likely switch to 5-year screening intervals.
• Only 0.8% of intermediate-risk men (13 of 1,661) had aggressive prostate cancer (grade groups 3–5) over 5 years.
• 78% of all biopsies in this group found no cancer or only harmless low-grade cancer, calling frequent screening into question.
• MRI is not a reliable pre-biopsy test in young men because it often misses low- and intermediate-grade prostate cancers.
• Active surveillance for grade group 1 or 2 prostate cancer showed no metastasis after 24 months in PROBASE participants.

Why This Research Matters

Prostate cancer is one of the most commonly diagnosed cancers in men, but not all prostate cancers are created equal. Some grow aggressively and can spread, while others remain harmless for decades and never cause symptoms or threaten a man's life. The challenge for doctors and patients is distinguishing between these two types — and avoiding unnecessary treatment for the harmless ones.

Current screening programs for prostate cancer lack specificity. This means that traditional PSA blood tests can flag men for further testing even when no dangerous cancer exists. Even modern risk-adapted screening programs, such as the Organized Prostate Cancer Testing (OPT) program in Sweden, still result in unnecessary diagnostic tests and overdiagnosis. Overdiagnosis occurs when a cancer is detected that would never have caused symptoms or death — but once found, it often leads to anxiety and potentially unnecessary treatments like surgery or radiation.

The European Association of Urology (EAU) guidelines now recommend active surveillance (closely monitoring a cancer rather than treating it immediately) for grade group 1 (GG1) prostate cancer, and this approach can also be recommended for GG2 cancer when no adverse pathological features are present. Active surveillance typically involves regular PSA tests, repeat biopsies, and sometimes MRI scans, with treatment reserved for cancers that show signs of progression.

This raises a fundamental question: if we know that low-grade and even some intermediate-grade prostate cancers are slow-growing with low metastatic potential, why are we detecting them early through aggressive screening at all? This is the question the PROBASE trial sought to answer for young men, and the results have direct implications for how often men should be screened.

Understanding the PROBASE Screening Trial

PROBASE (which stands for "Prostate Cancer Screening Trial for Young Men") is a large, ongoing German randomized trial funded by Stiftung Deutsche Krebshilfe (the German Cancer Aid Foundation). It was designed to answer key questions about how and when to screen for prostate cancer in younger men, specifically those starting at age 45.

The rationale for starting screening at age 45 comes from the Malmö study, a landmark Swedish research project. That study demonstrated that a single PSA measurement taken at age 45 had much higher prognostic power for predicting metastatic prostate cancer 25 years later compared with baseline PSA measurements taken at older ages. In other words, a PSA test at 45 can tell you a lot about a man's future risk — making this age an ideal checkpoint for establishing a baseline.

In the first screening round of PROBASE, 23,301 participants were screened. Of these, only 48 prostate cancers were detected — a detection rate of just 0.2% — and four of those 48 cancers were GG3 or higher. This very low detection rate in young men has itself sparked debate about whether screening should start at age 45 at all, but the long-term prognostic value of early PSA testing may justify it.

The PROBASE trial uses a risk-adapted screening approach. Men are categorized by their PSA level at baseline:

• Low risk: PSA below 1.5 ng/ml — recommended to return for repeat screening after 5 years
• Intermediate risk: PSA between 1.5 and 2.99 ng/ml — currently recommended to return every 2 years
• High risk: PSA of 3 ng/ml or higher — referred for further evaluation, including biopsy

This intermediate-risk group is far from negligible in size. It accounts for 9.8% of the PROBASE screening population at baseline, and in the Swedish OPT program — which uses a slightly lower intermediate-risk cutoff of 1.0–2.99 ng/ml — it makes up a substantial 32% of all men screened. This means that decisions about how to manage intermediate-risk men affect a very large number of individuals and have major implications for healthcare resources.

How the Study Was Conducted

This analysis focused specifically on the intermediate-risk group (PSA 1.5–2.99 ng/ml) from the PROBASE trial. At the time of study enrollment, 2,290 men fell into this category. Since then, four men withdrew from the study with complete data erasure, leaving 2,286 evaluable men.

The researchers analyzed data from men who participated in up to two biennial (every 2 years) screening rounds. This included the 2-year screening round and the 4-year screening round (which is the second biennial round). The analysis was limited to the first 5 years in the study (up to age 50), and any PSA screening tests or prostate cancer diagnoses occurring later than 5 years after baseline were excluded.

Here's the breakdown of participation:

• 1,628 men (71% of the 2,286 eligible) complied with the 2-year screening round
• Of these, 131 had progressed to PROBASE "high risk" status by the 2-year mark
• 1,530 men who had not yet progressed to high risk completed the 4-year screening round
• An additional 116 men had progressed to high risk by the 4-year mark
• Overall, 1,661 men were evaluable for this analysis (approximately 73% of the eligible intermediate-risk group)

Biopsies were performed when a man had a confirmed PSA level of 3 ng/ml or higher in one of the screening rounds. Importantly, the biopsy indication was based on confirmed PSA level alone — MRI was not used as a triage (pre-screening) test before biopsy, as some other protocols do. Each prostate biopsy involved both MRI-guided targeted biopsy and systematic biopsy to maximize the chance of detecting any significant cancer.

The researchers examined the grade group distribution of all cancers found, the timing of diagnoses relative to baseline PSA measurement, and what would happen if the screening interval were extended from 2 years to 5 years for this intermediate-risk group.

Key Findings: What the Biopsies Revealed

Over the course of the 2-year and 4-year screening rounds, a total of 159 biopsies were performed among the intermediate-risk men — representing 10% of the 1,661 men evaluated. The results of these biopsies are striking.

Of the 159 biopsies:

• 100 were negative for cancer (63% of all biopsies; 6.0% of the screening population)
• 59 revealed prostate cancer (37% of all biopsies; 3.6% of the screening population)

When the positive biopsies were broken down by grade group, the distribution was:

• Grade group 1 (GG1): 22 cases (37% of positive biopsies; 1.3% of the screening population)
• Grade group 2 (GG2): 24 cases (41% of positive biopsies; 1.4% of the screening population)
• Grade group 3 (GG3): 8 cases (14% of positive biopsies; 0.5% of the screening population)
• Grade group 4 (GG4): 3 cases (5% of positive biopsies; 0.2% of the screening population)
• Grade group 5 (GG5): 2 cases (3% of positive biopsies; 0.1% of the screening population)

The timing of biopsies is also instructive. The table below shows when cancers were detected relative to the baseline PSA measurement:

• 2 to <3 years after baseline: 85 biopsies performed, 33 positive (13 GG1, 16 GG2, 2 GG3, 1 GG4, 1 GG5)
• 3 to <4 years after baseline: 11 biopsies performed, 4 positive (0 GG1, 3 GG2, 0 GG3, 1 GG4, 0 GG5)
• 4 to <5 years after baseline: 63 biopsies performed, 22 positive (9 GG1, 5 GG2, 6 GG3, 1 GG4, 1 GG5)

Looking at the aggressive cancers specifically, six GG3 cases were detected in the 2-year screening round (detection rate 6/1661 = 0.4%) and seven GG3 cases were detected in the 4-year round (detection rate 7/1661 = 0.4%). The total number of men with aggressive disease (GG3 or higher) was just 13 out of 1,661 — a rate of 0.8%.

Most importantly for the screening interval question: the combined proportion of men with GG1 (slow-growing, essentially harmless) or GG2 (favorable intermediate-risk) cancers was 78% of all positive biopsies (46 out of 59). This means that more than three-quarters of all cancers detected in this intermediate-risk group were types that active surveillance guidelines say may not need immediate treatment.

Understanding Grade Groups and Prostate Cancer Risk

For patients reading this, it's helpful to understand what grade groups mean. Grade groups are a system for classifying how abnormal prostate cancer cells look under a microscope compared with normal prostate cells — a higher grade means the cells look more abnormal and the cancer is more likely to grow and spread.

The International Society of Urological Pathology (ISUP) grade group system runs from 1 to 5:

• Grade group 1: The cancer cells look very similar to normal cells. These cancers are slow-growing and very unlikely to spread. Active surveillance is the standard recommendation.
• Grade group 2: Slightly more abnormal cells. These are considered "favorable intermediate-risk" cancers. Active surveillance can be recommended if no adverse features are present.
• Grade groups 3–5: Increasingly aggressive cancers with a higher risk of growing, spreading, and becoming life-threatening. These are the cancers that screening programs are designed to catch.

In this study, 78% of the positive biopsies were GG1 or GG2 — cancers that are slow-growing and have low metastatic potential (low risk of spreading to other parts of the body). This finding lies at the heart of the debate: are we subjecting young men to invasive procedures to find cancers that may never harm them?

What About Grade Group 2 Cancers?

Grade group 2 was the most common cancer found in the PROBASE intermediate-risk group, accounting for 41% of all prostate cancers detected. This is consistent with other screening programs: the proportion of GG2 cancers detected through PSA-based screening ranges from 44.5% in the Swedish OPT program (starting age 50) to 60.4% in PROBASE (starting age 45), both using a PSA cutoff of 3 ng/ml for biopsy.

The key question is: does finding and treating GG2 cancer early actually save lives? Evidence from multiple sources suggests it may not. The ProtecT trial (a major UK study) followed men with prostate cancer for 15 years and found no difference in metastasis-free or overall survival between men with GG2 disease and those with GG1 disease, regardless of whether they received active monitoring, surgery, or radiotherapy. While the rate of metastasis was higher in the active monitoring group compared with the active treatment group, this did not translate into a difference in survival at 15 years.

The authors of this study make a critical observation: since GG2 cancers behave similarly to GG1 cancers in terms of survival outcomes, they are unlikely to progress significantly if diagnosis is delayed by a few years. In short, a cancer that is truly GG2 — not harboring hidden aggressive components — is not an emergency. The likelihood that these cancers will progress if diagnosis is delayed by a couple of years is very low.

Active Surveillance: Evidence from PROBASE

Further evidence supporting a more relaxed approach to GG2 cancers comes from the active surveillance data within PROBASE itself. Among patients who underwent active surveillance after a diagnosis of GG1 or GG2 prostate cancer (representing 30% of all GG1 and GG2 cases in the trial), the outcomes were reassuring.

Of the 91 patients on active surveillance, 20% had GG2 prostate cancer. After a mean treatment-free survival of 24 months:

• Only 1 of the 13 men who ultimately underwent radical prostatectomy (surgical removal of the prostate) had adverse pathological features (specifically, pT3, meaning the cancer had begun to penetrate the prostate capsule)
• None of these men had metastasis at the time of surgery
• 12 out of 13 men with PSA follow-up did not experience biochemical recurrence (a rise in PSA suggesting the cancer may have returned)

This suggests that even when men on active surveillance eventually require surgery, the outcomes are generally excellent — and a delay of a few years in diagnosing these cancers is unlikely to compromise treatment success. The beneficial outcomes of active surveillance in GG2 patients are further supported by the PRIAS trial and other European cohort studies.

The Case for 5-Year Screening Intervals

So what would happen if the screening interval for intermediate-risk men were extended from 2 years to 5 years, matching the interval currently used for low-risk men? The researchers worked through the numbers, and the benefits are substantial.

First, extending the interval would save numerous invitations to screening and PSA tests for the two biennial screening rounds. The logistical and financial savings of eliminating these tests for about 10% of the entire screening population would be meaningful for any healthcare system.

Second, 60% of negative biopsies could be avoided or delayed. In this study, that represents 100 men who underwent an invasive biopsy procedure — with its risks of pain, bleeding, infection, and anxiety — only to learn they had no cancer.

Third, overdiagnosis of GG1 prostate cancer could be prevented in 32–39% of men. In this cohort, that's 22 men diagnosed with a harmless cancer that would never have caused symptoms or death but will now require monitoring and may lead to anxiety and potentially unnecessary treatment.

Adding these together, 122 out of 159 invasive interventions (78%) resulted in "undesired findings" — either a negative biopsy or detection of a GG1 cancer. The authors note that this high proportion of interventions with undesired results "calls the legitimacy of this practice into question."

But what about the cost of this approach? If intermediate-risk men were screened at 5-year intervals instead of 2-year intervals, 22% of aggressive cancers (GG3) would not be detected in the 2-year screening round. Instead, their diagnosis would be delayed — by 1 year for cancers that would otherwise have been detected at the 4-year screening round, or by 3 years for cancers that would otherwise have been found at the 2-year screening round.

The absolute number of such cases is very small. Only 13 of 1,661 men (0.8%) in the entire intermediate-risk group had GG3–5 prostate cancer. The detection yield for aggressive cancer was extremely low in both screening rounds — just 0.4% in each round. In other words, screening 1,661 men every 2 years for 5 years would catch only about 13 aggressive cancers that a 5-year interval would have delayed. Most of those, based on the evidence from ProtecT and active surveillance studies, would still have been curable with a delay of 1 to 3 years.

Why MRI Isn't a Simple Solution

One might wonder: could MRI help identify which men really need a biopsy, thereby solving the overdiagnosis problem? Unfortunately, the evidence from PROBASE suggests that MRI is not a reliable solution in this age group.

Detection of GG1 and GG2 prostate cancer via MRI is difficult in young men. The authors note that MRI does not seem to be a reliable reflex test for detecting low- and intermediate-grade cancers in this population. This means that relying on MRI to triage which men get biopsies could miss a significant number of the very cancers that screening is designed to find — or alternatively, could still flag many harmless cancers. MRI has limited ability to visualize low-grade tumors in the prostate, particularly in younger men who may have fewer distinguishing features on imaging.

Limitations of the Study

As with any research, it's important to understand what this study could and could not prove. The authors acknowledge several important limitations:

Short follow-up period. This analysis was limited to the first 5 years of the study (up to age 50). Prostate cancer is a disease that can take decades to become clinically significant, so longer follow-up is needed to confirm that delayed detection of GG3–5 cancers doesn't lead to worse long-term outcomes. The researchers plan to continue tracking these men.

Sample size considerations. While 1,661 men is a substantial cohort, the number of aggressive cancers (13 total) is very small. This makes it difficult to draw definitive conclusions about what happens to men with GG3–5 cancer whose diagnosis is delayed.

Participation rate. Only 73% of eligible men were included in the analysis, and 29% did not comply with the 2-year screening round. Men who skip screenings may differ systematically from those who attend — for example, they may have different health behaviors or risk profiles.

Generalizability. The PROBASE trial is conducted in Germany, and the study population is predominantly European. Results may not translate directly to other ethnic groups or healthcare systems with different screening protocols.

PSA-only biopsy referral. Because biopsies were triggered by PSA alone without MRI triage, the rate of negative biopsies might be higher than in programs that use MRI as a pre-biopsy screening tool. This could inflate the "undesired findings" rate compared with other screening strategies.

The GG2 uncertainty. While the ProtecT trial showed no survival difference between GG1 and GG2 at 15 years, some GG2 cancers do harbor more aggressive features that aren't visible on initial biopsy. The study can't fully exclude the possibility that a small subset of GG2 cancers would benefit from earlier detection and treatment.

Compliance with 5-year intervals. The study models what would happen if men returned at 5-year intervals, but real-world compliance with longer intervals may be lower. Some men who are told to return in 5 years may never come back, which could have different implications than the model predicts.

What This Means for Patients

So, what should a 45-year-old man with a PSA between 1.5 and 2.99 ng/ml take away from this research?

First, it's important to understand that an intermediate PSA level is not a diagnosis of cancer — it's a risk marker. In this study, 90% of men with intermediate PSA levels had no cancer detected that required treatment during the study period. Only 0.8% were found to have an aggressive cancer (GG3–5).

The study's core recommendation is:

1. Men aged 45 with intermediate baseline PSA levels (1.5–2.99 ng/ml) can safely undergo repeat screening every 5 years instead of every 2 years, aligning them with the schedule already used for low-risk men.
2. If adopted, this change would not mean ignoring risk — it would mean retesting at an appropriate interval based on evidence about how slowly these cancers progress. Men in the intermediate-risk group should still be invited for repeat screening; the invitation just comes later.
3. Men who do progress to high-risk PSA levels (≥3 ng/ml) should still undergo biopsy evaluation as recommended — the 5-year interval only applies to men whose PSA remains in the intermediate range.

The authors estimate that implementing this adjusted screening strategy for approximately 10% of the screened population could substantially reduce unnecessary testing and overdiagnosis in a large cohort of young men. It would also make prostate cancer screening programs "more efficient and less burdensome for patients and healthcare systems."

For men who are diagnosed with GG1 or GG2 prostate cancer, the findings reinforce the safety of active surveillance as a first-line approach. In the PROBASE active surveillance cohort, after 24 months of follow-up, not a single man developed metastasis, and only one of 13 who eventually had surgery had unfavorable pathology. These are reassuring numbers.

It's also worth noting the bigger picture: the overall prostate cancer detection rate in PROBASE's first screening round was just 0.2% — one cancer for every 500 men screened. This very low yield raises legitimate questions about whether routine screening should begin at age 45 at all, outside of the risk-stratified approach used in the trial. The long-term prognostic value of a baseline PSA at 45 (so powerfully demonstrated by the Malmö study) suggests that this age is valuable as a risk-stratification checkpoint — but not necessarily as a time for aggressive cancer hunting.

Patients should discuss their individual risk profile with their urologist or primary care physician. Decisions about screening intervals should take into account not just PSA levels but also family history, ethnicity, prior biopsy results, and overall health status. This study provides strong evidence that, for most men with intermediate PSA levels at age 45, the anxiety, cost, and potential harm of biennial screening outweigh the benefits — and that waiting 5 years is both safe and sensible.

Frequently Asked Questions

What does an intermediate PSA level mean for a 45-year-old man?

An intermediate PSA level (1.5–2.99 ng/ml) is a risk marker, not a cancer diagnosis. In a German screening trial, 90% of men with this level had no cancer needing treatment during the study. Only 0.8% had an aggressive cancer. Your doctor will use this level to decide when you need repeat testing.

Should I get screened every 2 years or every 5 years if my PSA is intermediate?

New research from the PROBASE trial in Germany suggests that healthy 45-year-old men with PSA levels between 1.5 and 2.99 ng/ml can safely switch to screening every 5 years instead of every 2 years. This could reduce unnecessary biopsies and overdiagnosis. Men whose PSA rises to 3 ng/ml or higher still need prompt evaluation.

What are grade groups and how do they affect my risk?

Grade groups classify how abnormal prostate cancer cells look under a microscope. Grade group 1 cancers are slow-growing and very unlikely to spread. Grade group 2 is considered favorable intermediate-risk. Grade groups 3–5 are increasingly aggressive and are the cancers screening aims to catch. Your grade group guides treatment decisions.

Is it safe to delay screening to 5 years? Will I miss an aggressive cancer?

In the PROBASE trial, delaying screening from 2 to 5 years in intermediate-risk men would delay detection of a small number of aggressive cancers. Only 13 of 1,661 men (0.8%) had aggressive cancer. Evidence suggests most of these cancers would still be curable with a delay of 1 to 3 years.

What are 'undesired findings' in prostate cancer screening?

In the PROBASE trial, 78% of biopsies in intermediate-risk men resulted in either a negative biopsy or detection of grade group 1 cancer—findings many experts consider undesirable. These outcomes cause unnecessary anxiety, cost, and potential harm from overtreatment. The researchers question whether such frequent screening is justified for this group.

Can MRI help avoid unnecessary biopsies in young men?

According to the PROBASE trial, MRI is not a reliable solution for deciding which young men need a biopsy. MRI has difficulty detecting low- and intermediate-grade prostate cancers in younger men. Relying on MRI could miss significant cancers or still flag many harmless ones, so it is not used as a triage test in this trial.

What should I do if I'm diagnosed with GG1 or GG2 prostate cancer?

Active surveillance is a safe first-line approach for many grade group 1 or 2 prostate cancers. In PROBASE, 91 patients on active surveillance had no metastasis after 24 months. Only 1 of 13 who eventually had surgery had unfavorable pathology, and outcomes were excellent. Discuss with your doctor whether active surveillance is appropriate for you.

When should a 45-year-old man with an intermediate PSA level seek a second opinion about prostate cancer screening or a low-grade cancer diagnosis?

A 45-year-old man with a PSA of 1.5–2.99 ng/ml may consider a second opinion if his physician recommends biennial biopsies or immediate treatment for low-grade cancer. In the PROBASE trial, 90% of such men had no cancer needing treatment, and only 0.8% had aggressive disease. Most positive biopsies were GG1 or GG2, which often qualify for active surveillance rather than immediate surgery or radiation. A second opinion can help confirm whether 5-year screening intervals are appropriate or whether active surveillance is safe. Diagnostic Detectives Network provides independent expert second opinions.

Source Information

Original article title: Do We Need Early Detection of Grade Group 2 Prostate Cancer in a Screening Program for Young Men? Results from the PROBASE Screening Trial

Lead author: Peter Albers, MD, on behalf of the PROBASE trial group

Journal: European Urology Oncology, 2025 (Epub ahead of print)

DOI: 10.1016/j.euo.2025.06.007

Key institutions: German Cancer Research Center (DKFZ), Heidelberg; University Hospitals in Düsseldorf, Hannover, Munich, Essen, and Bonn; and other German research centers.

Funding: The PROBASE trial is fully funded by Stiftung Deutsche Krebshilfe (German Cancer Aid Foundation; grant 70114830).

This patient-friendly article is based on peer-reviewed research. The original article is published as an open-access paper under the CC BY license. This summary is intended for educational purposes and does not constitute medical advice. Patients should always consult their healthcare providers about their individual screening and treatment decisions.